In diseases where autoantibody-mediated activation of the CP drives pathology, such as AQP4 + NMOSD, GBS, and MG, selective inhibition of C1s or C1q can reduce immune complex-driven inflammation without compromising the alternative or lectin pathways. This evidence concerns the gene CP and Guillain-Barre syndrome.